Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of crohn's disease in adults

Digestive Diseases and Sciences

Volumn 58, Issue 5, 2013, Pages 1329-1334

  Hirai, Fumihito ^a   Ishihara, Hiroshi ^a   Yada, Shinichirou ^b   Esaki, Motohiro ^b   Ohwan, Tomohisa ^c   Nozaki, Ryoichi ^c   Ashizuka, Shinya ^d   Inatsu, Haruhiko ^d   Ohi, Hidehisa ^e   Aoyagi, Kunihiko ^f   Mizuta, Yohei ^g   Matsumoto, Takayuki ^b   Matsui, Toshiyuki ^a  

^a Fukuoka University Chikushi Hospital   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c TAKANO HOSPITAL   (Japan)

^d UNIVERSITY OF MIYAZAKI   (Japan)

^e IMAMURA GENERAL HOSPITAL   (Japan)

^f FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Menoto Hospital   (Japan)

Author keywords

Crohn's disease; Enteral nutrition; Infliximab; Loss of response

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DIET THERAPY; ENTERIC FEEDING; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFUSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CROHN DISEASE; ENTERAL NUTRITION; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84878702445     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2374-2     Document Type: Article

References (30)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
3. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
4. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593-1610.
5. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009;104:760-767.
6. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;15:1383-1395.
7. Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386-388.
8. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther. 2000;14:281-289.
9. Yamamoto T, Nakahigashi M, Saniabadi AR, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn's disease: a prospective study. Inflamm Bowel Dis. 2007;13:1493-1501.
10. Guzy C, Schirbel A, Paclik D, et al. Enteral and parenteral nutrition distinctively modulate intestinal permeability and T cell function in vitro. Eur J Nutr. 2009;48:12-21.
11. Learch ST, Mitchell HM, Eng WR, et al. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. Aliment Pharmacol Ther. 2008;28:724-733.
12. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55:i16-35.
13. Berni Canani R, Terrin G, Borrelli O, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis. 2006;38:381-387.
14. Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24:1333-1340.
15. Takagi S, Utsunomiya K, Kuriyama S, et al. Quality of life of patients and medical cost of "half elemental diet" as maintenance therapy for Crohn's disease: secondary outcomes of a randomised controlled trial. Dig Liver Dis. 2009;41:390-394.
16. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009;58:492-500.
17. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.
18. Greenstein AJ, Lachman P, Sachar DB, et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut. 1988;29:588-592.
19. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
20. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009;104:760-767.
21. Verma S, Kirkwood B, Brown S, et al. Oral nutritional supplementation is effective in the maintenance of remission in Crohn's disease. Dig Liver Dis. 2000;32:769-774.
22. Esaki M, Matsumoto T, Hizawa K, et al. Preventive effect of nutritional therapy against postoperative recurrence of Crohn's disease, with reference to findings determined by intra-operative enteroscopy. Scand J Gastroenterol. 2005;40:1431-1437.
23. Tanaka T, Takahama K, Kimura T, et al. Effect of concurrent elemental diet on infliximab treatment for Crohn's disease. J Gastroenterol Hepatol. 2006;21:1143-1149.
24. Song XM, Gao X, Li MZ, et al. Clinical features and risk factors for primary surgery in 205 patients with Crohn's disease: analysis of a South China cohort. Dis Colon Rectum. 2011;54:1147-1154.
25. Seksik P, Nion-Larmurier I, Sokol H, et al. Effects of light smoking consumption on the clinical course of Crohn's disease. Inflamm Bowel Dis. 2009;15:734-741.
26. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-712.
27. Consigny Y, Modigliani R, Colombel JF, et al. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis. 2006;12:551-557.
28. Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:421-427.
29. Reinisch W, Wang Y, Oddens BJ, et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568-576.
30. Yamamoto T, Nakahigashi M, Umegae S, et al. Prospective clinical trial: enteral nutrition during maintenance infliximab in Crohn's disease. J Gastroenterol. 2010;45:24-29.